NT-219 is an innovative, first-in-class small molecule designed to overcome cancer drug resistance. NT-219 targets two proteins involved in the anticancer drug resistance mechanism – IRS1/2 and STAT3.
Outstanding efﬁcacy in preventing acquired resistance and reversing tumor resistance was demonstrated in various PDX models where NT-219 was administered in combination with various oncology therapies. These include EGFR Antibodies (Erbitux®), small molecular inhibitors of MEK (Mekinist®), mutated BRAF (Zelboraf®), EGFR (Tagrisso®, Tarceva®), and mTOR (Afinitor®), as well as with chemotherapy agents such as Gemcitabine, Oxaliplatin, and Docetaxel. Preliminary synergistic effects were also observed in combination with immune oncology agents such as Keytruda®.